hypofractionated radiotherapy for stage i squamous cell carcinoma glottis: an experience with 60gy in 20 fractions

Introduction: early-stage glottic cancer has a high cure rate with definitive radiotherapy. historical reports show excellent local control. the present study evaluated the outcomes of early glottic cancer patients treated with a hypofractionated radiotherapy schedule of 60gy in 20 fractions. material and methods: this is a retrospective study of patients with stage i glottic cancer who received radical intent linac-based hypo-fractionated 3d conformal radiotherapy with a dose 60gy in 20 fractions. the primary objective was to assess the locoregional control (lrc), and secondary objectives were to determine disease-free survival (dfs), overall survival (os), and toxicity.results: the analysis included 105 patients from the age range of 35-88 years. about 69% of patients were over 60 years of age. the median overall treatment time (ott) was 26 days (24 – 30 days). the mean follow-up was 74 months, ranging from 9 to 135 months. seven patients had locoregional recurrence after an initial complete clinical response. six had local, and one had a regional nodal recurrence. dfs at five years and ten years were 83% and 69%, and os at five years and ten years were 87% and 80%, respectively. most patients reported grade i skin reactions and tolerated the treatment well. we did not observe any late adverse events such as persistent laryngeal edema or radiation necrosis.conclusion: the radiotherapy schedule of 60gy in 20 fractions over four weeks offers comparable local disease control with reasonable long-term side effects in t1 glottic cancer.